Affiliation:
1. Department of Biosciences, School of Liberal Arts and Sciences, Mody University of Science and Technology, Lakshmangarh 332311, Rajasthan, India
2. Department of Medicine, Pennsylvania State University, Hershey Medical Centre, Hershey, PA 17033, USA
Abstract
Chronic infections often involve notorious pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, demanding innovative antimicrobial strategies due to escalating resistance. This investigation scrutinized the antibacterial prowess of bile salts, notably taurocholic acid (TCA), ursodeoxycholic acid (UDCA), and ox bile salt (OBS), against these pathogens. Evaluations encompassed minimum inhibitory concentration (MIC) determination, scrutiny of their impact on biofilm formation, and anti-virulence mechanisms. UDCA exhibited the highest efficacy, suppressing S. aureus and P. aeruginosa biofilms by 83.5% and 78%, respectively, at peak concentration. TCA also significantly reduced biofilm development by 81% for S. aureus and 75% for P. aeruginosa. Microscopic analysis revealed substantial disruption of biofilm architecture by UDCA and TCA. Conversely, OBS demonstrated ineffectiveness against both pathogens. Mechanistic assays elucidated UDCA and TCA’s detrimental impact on the cell membrane, prompting the release of macromolecular compounds. Additionally, UDCA and TCA inhibited protease and elastase synthesis in P. aeruginosa and staphyloxanthin and lipase production in S. aureus. These results underscore the potential of UDCA and TCA in impeding biofilm formation and mitigating the pathogenicity of S. aureus and P. aeruginosa.
Funder
CURIE Core Grants for Women Universities
Reference35 articles.
1. Discovery and preclinical development of new antibiotics;Diarmaid;Upsala J. Med. Sci.,2014
2. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics;Renwick;J. Antibiot.,2016
3. Renwick, M.J., Simpkin, V., and Mossialos, E. (2016). Targeting Innovation in Antibiotic Drug Discovery and Development: The Need for a One-Health, One-Europe, One-World Framwork, European Observatory on Health Systems and Policies. Health Policy Series No. 45.
4. (2022). 2021 Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis, World Health Organization.
5. The biofilm matrix—An immobilized but dynamic microbial environment;Sutherland;Trends Microbiol.,2001